| 2.77 0.03 (1.09%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.29 | 1-year : | 5.06 |
| Resists | First : | 3.67 | Second : | 4.34 |
| Pivot price | 3.23 |
|||
| Supports | First : | 2.59 | Second : | 2.16 |
| MAs | MA(5) : | 2.91 |
MA(20) : | 3.3 |
| MA(100) : | 3.99 |
MA(250) : | 8.51 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 8.8  |
D(3) : | 7.7 |
| RSI | RSI(14): 31.2 |
|||
| 52-week | High : | 32.4 | Low : | 2.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BCTX ] has closed above bottom band by 9.0%. Bollinger Bands are 25.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.89 - 2.91 | 2.91 - 2.93 |
| Low: | 2.59 - 2.61 | 2.61 - 2.63 |
| Close: | 2.74 - 2.77 | 2.77 - 2.8 |
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
Tue, 09 Jun 2026
BriaCell (NASDAQ: BCTX) ramps cancer trials but flags going concern risk - Stock Titan
Wed, 03 Jun 2026
BriaCell Therapeutics Prices $4.71 Million Share Offering at $3.25; ThinkEquity as Placement Agent - TradingView
Tue, 02 Jun 2026
BriaCell Therapeutics Announces Closing of Offering - Investing News Network
Tue, 02 Jun 2026
BriaCell (NASDAQ: BCTX) completes $4.71M best efforts common share sale - Stock Titan
Mon, 01 Jun 2026
BriaCell Presents Positive Clinical Data at ASCO 2026 - markets.businessinsider.com
Sun, 31 May 2026
What Does BriaCell's Latest Offering Mean for Shareholders - Kavout
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 470 (K) |
| Shares Short P.Month | 227 (K) |
| EPS | -14.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -89.5 % |
| Return on Equity (ttm) | -179.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.2 |
| PEG Ratio | 0 |
| Price to Book value | 0.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|